肝细胞癌过继细胞免疫治疗研究进展

李艳; 严胡铃; 石瑛; 张第; 黄孝伦

doi:10.3969/j.issn.1001-5256.2020.08.038

肝细胞癌过继细胞免疫治疗研究进展

DOI: 10.3969/j.issn.1001-5256.2020.08.038

电子科技大学附属医院·四川省人民医院细胞移植中心

基金项目:

2018年四川省科技厅重大研究计划(2018SZ0110)； 2019年四川省国际科技创新合作/港澳台科技创新合作项目(2019YFH0074)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 726
- HTML全文浏览量: 21
- PDF下载量: 194
- 被引次数: 0
出版历程
- 出版日期: 2020-08-20

Research advances in adoptive cell transfer immunotherapy for hepatocellular carcinoma

Cell Transplant Center, The Affiliated Hospital of University of Electronic Science and Technology of China & Sichuan Provincial People’s Hospital

Research funding:

摘要

摘要:
我国肝癌患者的病死率正在不断上升,严重威胁着人类的健康,因此急需探索出更多有效的治疗方法以延长患者的生存时间。肝脏由于其特殊的生理结构特点而发挥着免疫调节功能,基于此,肝癌的免疫治疗逐渐表现出了其临床优势,成为继手术、化疗、放疗后第四种肝癌治疗方法。过继细胞免疫疗法近几年在肝细胞癌的治疗中发展迅速。用于过继细胞免疫治疗的免疫细胞有CIK、NK、DC-CIK、TIL、CAR-T细胞,简单概述了这几种过继免疫细胞在肝细胞癌治疗中的研究现状及临床进展。
- 癌,肝细胞 /
- 免疫疗法,过继 /
- 治疗学
Abstract:
The mortality rate of liver cancer patients in China is increasing constantly,which greatly threatens human health,and therefore,it is urgent to explore more effective treatment methods to prolong the survival time of patients.Because of its special physiological structure,the liver plays an immunoregulatory role,and thus immunotherapy for liver cancer gradually shows its clinical advantages and has become the fourth-generation therapy for liver cancer after surgical resection,chemotherapy,and radiotherapy.Adoptive cell transfer immunotherapy has been developed rapidly in the treatment of hepatocellular carcinoma(HCC) in recent years.CIK,NK,DC-CIK,TIL,and CAR-T cells are immune cells used for adoptive cell transfer immunotherapy.This article briefly summarizes the research advances in these immune cells in the treatment of HCC.
- carcinoma,hepatocellular /
- immunotherapy,adoptive /
- therapeutics

HTML全文

参考文献(50)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] LI J,HUANG L,YAN J,et al. Liver resection for hepatocellular carcinoma:Personal experiences in a series of 1330 consecutive cases in China[J]. ANZ J Surg,2018,88(10):e713-e717.

[3] MARUBASHI S,GOTOH K,AKITA H,et al. Anatomical versus non-anatomical resection for hepatocellular carcinoma[J]. Br J Surg,2015,102(7):776-784.

[4] LU PH,NEGRIN RS. A novel population of expanded human CD3+CD56+cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency[J]. J Immunol,1994,153(4):1687-1696.

[5] LINN YC,LAU SK,LIU BH,et al. Characterization of the recognition and functional heterogeneity exhibited by cytokineinduced killer cell subsets against acute myeloid leukaemia target cell[J]. Immunology,2009,126(3):423-435.

[6] PAN QZ,LIU Q,ZHOU YQ,et al. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma[J]. Cancer Immunol Immunother,2020,69(5):825-834.

[7] LEE JH,LEE JH,LIM YS,et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology,2015,148(7):1383-1391.

[8] LEE JH,LEE JH,LIM YS,et al. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma:An extended 5-year follow-up[J].Cancer Immunol Immunother,2019,68(1):23-32.

[9] YOON JS,SONG BG,LEE JH,et al. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma:A propensity score-matched analysis of real-world data[J].BMC Cancer,2019,19(1):523.

[10] YU SJ,MA C,HEINRICH B,et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma[J]. J Hepatol,2019,70(3):449-457.

[11] ZHANG J,WU N,LIAN Z,et al. The combined antitumor effects of(125)I radioactive particle implantation and cytokine-induced killer cell therapy on xenograft hepatocellular carcinoma in a mouse model[J]. Technol Cancer Res Treat,2017,16(6):1083-1091.

[12] HUANG F,WANG B,ZENG J,et al. MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells[J]. Oncol Lett,2018,15(4):4797-4804.

[13] CHEN M,XU M,ZHU C,et al. Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model[J]. Cancer Immunol Immunother,2019,68(6):961-971.

[14] CHOI JW,LEE ES,KIM SY,et al. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes(MYJ1633)against liver cancer[J]. BMC Cancer,2019,19(1):817.

[15] PARKHURST MR,RILEY JP,DUDLEY ME,et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression[J]. Clin Cancer Res,2011,17(19):6287-6297.

[16] SAKAMOTO N,ISHIKAWA T,KOKURA S,et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer[J]. J Transl Med,2015,13:277.

[17] MILLER JS,SOIGNIER Y,PANOSKALTSIS-MORTARI A,et al.Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer[J]. Blood,2005,105(8):3051-3057.

[18] QIN Z,CHEN J,ZENG J,et al. Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma:A preliminary clinical study[J]. Cancer Biol Ther,2017,18(5):323-330.

[19] YANG Y,QIN Z,DU D,et al. Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer[J]. Cardiovasc Intervent Radiol,2019,42(1):48-59.

[20] XIE S,WU Z,ZHOU L,et al. Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation:A case report[J].Onco Targets Ther,2018,11:7345-7352.

[21] EL ANSARY M,MOGAWER S,ELHAMID SA,et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J]. J Cancer Res Clin Oncol,2013,139(1):39-48.

[22] JUNG NC,LEE JH,CHOI HJ,et al. Dendritic cell immunotherapy combined with cytokine-induced killer cells effectively suppresses established hepatocellular carcinomas in mice[J]. Immunol Invest,2016,45(6):553-565.

[23] CAO J,KONG FH,LIU X,et al. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma:A meta-analysis[J]. World J Gastroenterol,2019,25(27):3649-3663.

[24] KUDO M,FINN RS,QIN S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.

[25] ZHOU Z,QIN H,WENG L,et al. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma[J]. J BUON,2019,24(2):615-621.

[26] HE G,ZHENG C,HUO H,et al. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma:A meta-analysis[J]. Int Immunopharmacol,2016,40:436-442.

[27] ZHANG J,LI H,GAO D,et al. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE[J]. Cancer Biol Ther,2018,19(6):475-483.

[28] MA YJ,HE M,HAN JA,et al. A clinical study of HBs Ag-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B[J]. Scand J Immunol,2013,78(4):387-393.

[29] ZHOU P,LIANG P,DONG B,et al. PhaseⅠclinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma[J]. Cancer Biol Ther,2011,11(5):450-456.

[30] DUDLEY ME,GROSS CA,SOMERVILLE RP,et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma[J]. J Clin Oncol,2013,31(17):2152-2159.

[31] BEN-AVI R,ITZHAKI O,SIMANSKY D,et al. Metastatic lung lesions as a preferred resection site for immunotherapy with tumor infiltrating lymphocytes[J]. J Immunother,2016,39(5):218-222.

[32] DONIA M,LARSEN SM,MET O,et al. Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor[J]. Cytotherapy,2014,16(8):1117-1120.

[33] TAVERA RJ,FORGET MA,KIM YU,et al. Utilizing T-cell activation signals 1,2,and 3 for tumor-infiltrating lymphocytes(TIL)expansion:The advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma[J]. J Immunother,2018,41(9):399-405.

[34] YUNGER S,BAR EL A,ZELTZER LA,et al. Tumor-infiltrating lymphocytes from human prostate tumors reveal antitumor reactivity and potential for adoptive cell therapy[J]. Oncoimmunology,2019,8(12):e1672494.

[35] WANG Y,CHEN H,WU M,et al. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes[J]. Chin Med J(Engl),1997,110(2):114-117.

[36] ROSENBERG SA,SPIESS P,LAFRENIERE R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes[J]. Science,1986,233(4770):1318-1321.

[37] CHANDRAN SS,SOMERVILLE R,YANG JC,et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes:A single-centre,two-stage,single-arm,phase 2 study[J]. Lancet Oncol,2017,18(6):792-802.

[38] NGUYEN LT,SAIBIL SD,SOTOV V,et al. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and lowdose interleukin-2[J]. Cancer Immunol Immunother,2019,68(5):773-785.

[39] JIANG SS,TANG Y,ZHANG YJ,et al. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma[J]. Oncotarget,2015,6(38):41339-41349.

[40] GAO H,LI K,TU H,et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma[J]. Clin Cancer Res,2014,20(24):6418-6428.

[41] JIANG Z,JIANG X,CHEN S,et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma[J]. Front Immunol,2016,7:690.

[42] PAN Z,DI S,SHI B,et al. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein[J]. Cancer Immunol Immunother,2018,67(10):1621-1634.

[43] GUO X,JIANG H,SHI B,et al. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma[J]. Front Pharmacol,2018,9:1118.

[44] LIU Y,DI S,SHI B,et al. Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma[J]. J Immunol,2019,203(1):198-207.

[45] BATRA SA,RATHI P,GUO L,et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma[J]. Cancer Immunol Res,2020,8(3):309-320.

[46] ADACHI K,KANO Y,NAGAI T,et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J]. Nat Biotechnol,2018,36(4):346-351.

[47] WEI WY,BEICHENG S. Anti-GPC3 CAR-T therapy suppresses hepatocarcinoma and IL7 and CCL19 expression enhanced the infiltration of CAR-T cells in tumor[J]. HPB,2019,21:s403.

[48] LIU H,XU Y,XIANG J,et al. Targeting alpha-fetoprotein(AFP)-MHC complex with CAR T-cell therapy for liver cancer[J]. Clin Cancer Res,2017,23(2):478-488.

[49] ENBLAD G,KARLSSON H,GAMMELGRD G,et al. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia[J]. Clin Cancer Res,2018,24(24):6185-6194.

[50] GILL S,JUNE CH. Going viral:Chimeric antigen receptor Tcell therapy for hematological malignancies[J]. Immunol Rev,2015,263(1):68-89.

施引文献

资源附件(0)

访问统计